
### Volume 5, Issue 2

# Targeting Talk: Streptavidin versus Avidin

- *Q* I recently tried to order avidinylated-SAP and was told that this product has been replaced with a new product, streptavidin-SAP. Why did you replace avidinylated-SAP?
- A We initially had good results with avidinylated-SAP. It combined well with biotinylated antibody to produce extremely potent cytotoxic materials, and had low toxicity itself. However, the weaknesses of avidin are well-documented. Probably the most severe is its high isoelectric point that has been suggested to cause nonspecific binding. As we produced more batches of avidinylated-SAP and completed comparative studies, we in fact, found this to be the case.
- *Q I* use avidinylated-SAP to demonstrate that my antibody internalizes. It worked quite well for me.
- A A couple of months ago we received two reports from customers that they were seeing that, even in batches that had performed well in quality control testing, there was a non-specific cytotoxicity with some cells and/or cell lines. Since a major use of this material is to demonstrate internalization of the biotinylated targeting agent, this was an unacceptable situation.

KNRK cells are plated at 2500 cells/well and incubated overnight. Streptavidin-SAP is premixed with Biotinylated-IB4 in equimolar concentrations or added to a plate alone. Saporin, IB4-SAP, and the Streptavidin-SAP + Biotinylated-IB4 mixture are added in 10- $\mu$ l volumes and plates incubated 72 hrs. PMS/MTS is added and the plates are incubated 15-30 min, then read at 490 nm.



We changed to streptavidin to overcome these specificity issues. As shown in the figure above, streptavidin-SAP has an excellent capacity to transform a biotinylated reagent into a potent cytotoxic targeting vehicle, while streptavidin-SAP alone has no detectable cytotoxicity.

#### **Streptavidin-SAP Pricing**

IT-27-25	25 micrograms	\$165 (\$190)
IT-27-100	100 micrograms	\$625 (\$725)
IT-27-250	250 micrograms	\$1450 (\$1775)

Kits (pricing in parentheses) includes equal amounts of saporin



Society for Neuroscience October 23-27, 2004 San Diego, CA www.atsbio.com/golf



Join ATS at the Torrey Pines Golf Course

# Targeting Teaser Winners

Congratulations to the puzzle solvers from our last newsletter. Each winner receives \$100 credit towards research product purchases from Advanced Targeting Systems.

The solution to the puzzle was: Jumbles: PLANETS OPTICS

CALCULUS WESTMINSTER VELOCITY

#### Answer: SIR ISAAC NEWTON

WINNERS: Armando Poeppl, Univ Health Network \* Dr. Hilda Yu, Univ of CAIrvine \* Ching-Hui Yang, Univ Texas Health Ctr \* Douglas J. Taatjes, Univ Vermont \* Filomena Dimayuga, Univ Kentucky \* Greg Hickey, Massachusetts General Hospital \* Tanja Babic, Univ Western Ontario \* Seto Chice, SUNY HSC Brooklyn \* Michael Lebowitz, Panacea Pharmaceuticals Inc \* Robert Speth, Univ Mississippi \* Thomas Breithaupt, Des Moines Univ \* Dr. Carmen Diaconu, Institute of Virology **Isaac Newton** was born December 25, 1642 in Lincolnshire, England. His accomplishments in nathematics, <u>optics</u>, and physics laid the foundations for nodern science.

As a mathematician, Newton invented integral <u>calculus</u>, and jointly with Leibnitz, differential calculus.

Newton made a huge impact on theoretical astronomy. He defined the laws of motion and universal gravitation which he used to predict precisely the motions of stars, and the <u>planets</u> around the sun. The first law dealt with forces and changes in <u>velocity</u>. Newton also constructed the first reflecting telescope.

Newton died in London on March 20, 1727 and was buried in <u>Westminster</u> Abbey, the first scientist to be accorded this honor.



pcom